Literature DB >> 21455714

The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk.

Mitsuru Kaise1, Jun Miwa, Jun Tashiro, Yasukazu Ohmoto, Shingo Morimoto, Masayuki Kato, Mitsuyoshi Urashima, Masahiro Ikegami, Hisao Tajiri.   

Abstract

BACKGROUND: A valid biomarker for predicting the presence of gastric cancer may contribute to reducing deaths from this disease. Although pepsinogen (PG) testing has been introduced as a predictor, its predictive power is not satisfactory. We examined whether serum trefoil factor (TFF) could be a non-endoscopic predictor of the presence of gastric cancer.
METHODS: Gastric cancer patients who underwent preoperative endoscopy were sequentially recruited. Individuals who underwent a thorough medical checkup were enrolled as non-cancer controls. Serum levels of TFF1, TFF2, TFF3, Helicobacter pylori antibody, PG I, and PG II were examined.
RESULTS: We studied 192 gastric cancer patients aged 64.3 ± 9.7 years and 1254 non-cancer controls aged 52.3 ± 12.4 years. In the age/gender-matched analysis (187 cases and 561 controls), significant relationships were demonstrated between gastric cancer presence and TFF3 (P < 0.0001), the PGI/II ratio (P < 0.0001), H. pylori antibody (P = 0.001), TFF1 (P = 0.012), and TFF2 (P = 0.020). The area under the receiver-operating characteristic curve for predicting gastric cancer presence was comparably high for all factors (0.893) and for the combination of TFF3 and the PG test (0.883), but was significantly (P < 0.0001) lower for the PG test alone (0.823). A positive PG test showed a sensitivity of 67% and specificity of 82%, whereas a combination of TFF3 and PG testing showed a sensitivity of 80% and specificity of 80% in predicting the presence of gastric cancer.
CONCLUSION: The combination of serum TFF3 and PG testing might be a valid non-endoscopic biomarker for predicting the presence of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455714     DOI: 10.1007/s00535-011-0396-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  21 in total

1.  Comparing mass screening techniques for gastric cancer in Japan.

Authors:  Atsushi Tashiro; Masatoshi Sano; Koichi Kinameri; Kazutaka Fujita; Yutaka Takeuchi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

2.  The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer.

Authors:  K Miki; M Ichinose; N Kakei; N Yahagi; M Matsushima; S Tsukada; S Ishihama; Y Shimizu; T Suzuki; K Kurokawa
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

3.  The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study.

Authors:  A Fukao; Y Tsubono; I Tsuji; S HIsamichi; N Sugahara; A Takano
Journal:  Int J Cancer       Date:  1995-01-03       Impact factor: 7.396

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study.

Authors:  H Watabe; T Mitsushima; Y Yamaji; M Okamoto; R Wada; T Kokubo; H Doi; H Yoshida; T Kawabe; M Omata
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

6.  The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study.

Authors:  Yoshinori Oishi; Yutaka Kiyohara; Michiaki Kubo; Keiichi Tanaka; Yumihiro Tanizaki; Toshiharu Ninomiya; Yasufumi Doi; Kentaro Shikata; Koji Yonemoto; Tomoko Shirota; Takayuki Matsumoto; Mitsuo Iida
Journal:  Am J Epidemiol       Date:  2006-01-27       Impact factor: 4.897

7.  Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic.

Authors:  P Lao-Sirieix; A Boussioutas; S R Kadri; M O'Donovan; I Debiram; M Das; L Harihar; R C Fitzgerald
Journal:  Gut       Date:  2009-08-02       Impact factor: 23.059

8.  Plasma levels of trefoil factors are increased in patients with advanced prostate cancer.

Authors:  Else Marie Vestergaard; Michael Borre; Steen Seier Poulsen; Ebba Nexø; Niels Tørring
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

Review 9.  Are trefoil factors oncogenic?

Authors:  Jo K Perry; Nagarajan Kannan; Prudence M Grandison; Murray D Mitchell; Peter E Lobie
Journal:  Trends Endocrinol Metab       Date:  2007-12-03       Impact factor: 12.015

10.  Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas.

Authors:  E Bignotti; A Ravaggi; R A Tassi; S Calza; E Rossi; M Falchetti; C Romani; E Bandiera; F E Odicino; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

View more
  22 in total

1.  Comparison of serum trefoil factor 3 with the pepsinogen test for the screening of diffuse-type gastric cancer.

Authors:  Ju Yup Lee; Kyung Sik Park; Hyun-Gyo Lee; Won-Ki Baek; Kwang Bum Cho; Yoo Jin Lee; Yoon Suk Lee; Seung-Wan Ryu
Journal:  Clin Exp Med       Date:  2016-05-06       Impact factor: 3.984

2.  Expression of trefoil factors and TWIST1 in colorectal cancer and their correlation with metastatic potential and prognosis.

Authors:  Akram Yusup; Bailikezi Huji; Cheng Fang; Fei Wang; Tuerxunjiang Dadihan; Hai-Jiang Wang; Halmurat Upur
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

3.  Serum Trefoil Factor 3 as a Protein Biomarker for the Diagnosis of Colorectal Cancer.

Authors:  Qiang Li; Keke Wang; Chang Su; Jieyu Fang
Journal:  Technol Cancer Res Treat       Date:  2016-10-19

4.  Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker.

Authors:  Mitsuru Kaise; Jun Miwa; Ai Fujimoto; Jun Tashiro; Daisuke Tagami; Hiromi Sano; Yasukazu Ohmoto
Journal:  Gastric Cancer       Date:  2012-08-21       Impact factor: 7.370

Review 5.  Diagnosis and management of high risk group for gastric cancer.

Authors:  Hyuk Yoon; Nayoung Kim
Journal:  Gut Liver       Date:  2015-01       Impact factor: 4.519

6.  Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis.

Authors:  Soyoung Im; Changyoung Yoo; Ji-Han Jung; Hyun Joo Choi; Jinyoung Yoo; Chang Suk Kang
Journal:  Int J Med Sci       Date:  2012-12-30       Impact factor: 3.738

7.  Trefoil Factor 2 (TFF2) as a Surrogate Marker for Endocervical Gastric-type Carcinoma.

Authors:  Kiyokawa Takako; Lien Hoang; Cristina Terinte; Anna Pesci; Sarit Aviel-Ronen; Isabel Alvarado-Cabrero; Esther Oliva; Kay J Park; Robert A Soslow; Simona Stolnicu
Journal:  Int J Gynecol Pathol       Date:  2021-01       Impact factor: 3.326

8.  Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China.

Authors:  Zhigang Huang; Xie Zhang; Hongna Lu; Lina Wu; Danping Wang; Qiubo Zhang; Huaxin Ding
Journal:  BMC Gastroenterol       Date:  2014-04-11       Impact factor: 3.067

9.  Serum TFF3 may be a pharamcodynamic marker of responses to chemotherapy in gastrointestinal cancers.

Authors:  Li Xiao; Yun-Peng Liu; Chuan-Xing Xiao; Jian-Lin Ren; Bayasi Guleng
Journal:  BMC Clin Pathol       Date:  2014-06-14

10.  Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells.

Authors:  Vijay Pandey; Min Zhang; Qing-Yun Chong; Mingliang You; Ainiah Rushdiana Raquib; Amit K Pandey; Dong-Xu Liu; Liang Liu; Lan Ma; Sudhakar Jha; Zheng-Sheng Wu; Tao Zhu; Peter E Lobie
Journal:  Oncotarget       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.